[go: up one dir, main page]

UA90124C2 - Способ профилактики вич-инфекции с помощью тмс278 - Google Patents

Способ профилактики вич-инфекции с помощью тмс278

Info

Publication number
UA90124C2
UA90124C2 UAA200708560A UAA200708560A UA90124C2 UA 90124 C2 UA90124 C2 UA 90124C2 UA A200708560 A UAA200708560 A UA A200708560A UA A200708560 A UAA200708560 A UA A200708560A UA 90124 C2 UA90124 C2 UA 90124C2
Authority
UA
Ukraine
Prior art keywords
hiv
tmc278
infection
prevention
formulation
Prior art date
Application number
UAA200708560A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ливин Эльвир Колетти Берт
Паулус Джоаннес Леви
Ян Хиирс
Original Assignee
Тиботек Фармасьютикелз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тиботек Фармасьютикелз Лтд. filed Critical Тиботек Фармасьютикелз Лтд.
Publication of UA90124C2 publication Critical patent/UA90124C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Данное изобретение касается применения парентеральной композиции, которая содержит NNRTI TMC278, для продолжительной профилактики ВИЧ-инфекции у субъекта, который имеет риск инфицирования ВИЧ, которое включает периодическое введение указанной композиции через продолжительные интервалы времени.
UAA200708560A 2005-04-04 2006-04-04 Способ профилактики вич-инфекции с помощью тмс278 UA90124C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05102616 2005-04-04

Publications (1)

Publication Number Publication Date
UA90124C2 true UA90124C2 (ru) 2010-04-12

Family

ID=34939113

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200708560A UA90124C2 (ru) 2005-04-04 2006-04-04 Способ профилактики вич-инфекции с помощью тмс278

Country Status (29)

Country Link
US (6) US20080194601A1 (ru)
EP (1) EP1881848B1 (ru)
JP (2) JP5632579B2 (ru)
KR (1) KR101360851B1 (ru)
CN (2) CN101155599A (ru)
AP (1) AP2617A (ru)
AR (1) AR053571A1 (ru)
AU (1) AU2006231585B2 (ru)
BR (1) BRPI0607649B8 (ru)
CA (1) CA2602231C (ru)
CY (1) CY1113950T1 (ru)
DK (1) DK1881848T3 (ru)
EA (1) EA011420B1 (ru)
ES (1) ES2402864T3 (ru)
HK (1) HK1198936A1 (ru)
HR (1) HRP20130296T1 (ru)
IL (1) IL184744A (ru)
ME (1) ME01517B (ru)
MX (1) MX2007012277A (ru)
MY (1) MY150091A (ru)
NZ (1) NZ556659A (ru)
PL (1) PL1881848T3 (ru)
PT (1) PT1881848E (ru)
RS (1) RS52724B (ru)
SI (1) SI1881848T1 (ru)
TW (2) TWI457136B (ru)
UA (1) UA90124C2 (ru)
WO (1) WO2006106103A2 (ru)
ZA (1) ZA200708454B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
RS52821B2 (sr) * 2006-01-20 2021-07-30 Janssen Sciences Ireland Unlimited Co Dugotrajno tretiranje hiv-infekcije sa tcm278
HUE038797T2 (hu) * 2006-06-23 2018-11-28 Janssen Sciences Ireland Uc TMC278 vizes szuszpenziói
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
EP2381961B1 (en) * 2008-12-24 2016-09-14 Janssen Sciences Ireland UC Implantable devices for treating hiv
MY163383A (en) 2009-12-21 2017-09-15 Janssen Sciences Ireland Uc Degradable removable implant for the sustained release of an active compound
DE102011082871A1 (de) * 2011-09-16 2013-03-21 Florian, Prof. Dr. Lang Therapeutische und diagnostische Targets für Autoimmunität, inflammatorische Prozesse und/oder immuner Pathogenese und/oder von Erkrankungen, welche auf Autoimmunität, inflammatorische Prozessen und/oder immuner Pathogenese beruhen
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
MA38182A1 (fr) 2012-12-14 2018-04-30 Glaxosmithkline Llc Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih)
CN106999425A (zh) * 2014-09-26 2017-08-01 葛兰素史克知识产权第二有限公司 长效药物组合物
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
KR20240170635A (ko) 2023-05-24 2024-12-04 서울대학교산학협력단 R-루프의 생성을 저해시켜 hiv 감염을 억제하는 방법 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
US6258932B1 (en) 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
HUP0302631A2 (hu) 2000-03-30 2003-11-28 Bristol-Myers Squibb Co. Stavudint tartalmazó elnyújtott hatóanyag-kibocsátású szemcsék
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
ATE361059T1 (de) 2002-11-08 2007-05-15 Glaxo Group Ltd Antivirale zusammensetzungen
AU2003282883B2 (en) 2002-11-18 2008-12-04 Polaris Group Methods for inhibiting viral replication in vivo
CL2004000192A1 (es) 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
JP2006518373A (ja) 2003-02-21 2006-08-10 トリペップ アクチ ボラゲット Ｈｉｖ複製を抑制するためのグリシンアミド誘導体
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
RS52821B2 (sr) * 2006-01-20 2021-07-30 Janssen Sciences Ireland Unlimited Co Dugotrajno tretiranje hiv-infekcije sa tcm278
HUE038797T2 (hu) * 2006-06-23 2018-11-28 Janssen Sciences Ireland Uc TMC278 vizes szuszpenziói

Also Published As

Publication number Publication date
CY1113950T1 (el) 2016-07-27
KR20080009051A (ko) 2008-01-24
AU2006231585B2 (en) 2012-02-02
EP1881848A2 (en) 2008-01-30
CN103860560A (zh) 2014-06-18
US20080194601A1 (en) 2008-08-14
HK1198936A1 (en) 2015-06-19
US20220071997A1 (en) 2022-03-10
IL184744A0 (en) 2007-12-03
AU2006231585A1 (en) 2006-10-12
EA011420B1 (ru) 2009-02-27
ZA200708454B (en) 2009-03-25
AP2617A (en) 2013-03-18
AP2007004178A0 (en) 2007-10-31
CA2602231C (en) 2014-03-25
US20110077261A1 (en) 2011-03-31
JP2008534651A (ja) 2008-08-28
ME01517B (me) 2014-04-20
TW200709818A (en) 2007-03-16
IL184744A (en) 2015-05-31
PL1881848T3 (pl) 2013-06-28
BRPI0607649B8 (pt) 2021-05-25
ES2402864T3 (es) 2013-05-09
TWI457136B (zh) 2014-10-21
BRPI0607649A2 (pt) 2009-09-22
SI1881848T1 (sl) 2013-05-31
CA2602231A1 (en) 2006-10-12
JP2013079275A (ja) 2013-05-02
MY150091A (en) 2013-11-29
US10765674B2 (en) 2020-09-08
HK1117039A1 (en) 2009-01-09
BRPI0607649B1 (pt) 2019-08-06
AR053571A1 (es) 2007-05-09
CN101155599A (zh) 2008-04-02
PT1881848E (pt) 2013-04-15
JP5632579B2 (ja) 2014-11-26
EP1881848B1 (en) 2013-01-16
WO2006106103A3 (en) 2007-06-07
RS52724B (sr) 2013-08-30
DK1881848T3 (da) 2013-04-15
MX2007012277A (es) 2007-10-17
TW201414495A (zh) 2014-04-16
EA200702169A1 (ru) 2008-02-28
WO2006106103A2 (en) 2006-10-12
KR101360851B1 (ko) 2014-02-11
US20160151276A1 (en) 2016-06-02
US20160296519A1 (en) 2016-10-13
HRP20130296T1 (hr) 2013-04-30
NZ556659A (en) 2012-03-30
US20200397783A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
MY150717A (en) Long term treatment of hiv-infection with tmc278
UY30431A1 (es) Suspensiones acuosas de tmc278
CY1112292T1 (el) Χρηση του 2-6-(3-αμινο-πιπεριδιν-1-υλ)-3-μεθυλ-2,4-διοξο-3,4-διυδρο-2η-πυριδιν-1-υλμεθυλ-4-φθορο-βενζονιτριλιου για την αγωγη του διαβητη, του καρκινου, αυτοανοσων διαταραχων και της μολυνσεως hiv
PH12018500263A1 (en) Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
UA90124C2 (ru) Способ профилактики вич-инфекции с помощью тмс278
BR112015014562A2 (pt) composições pesticidas e processos com estas relacionados
AP2005003366A0 (en) Pyrimidine derivatives for the prevention of HIV infection.
ATE482953T1 (de) Hiv-inhibierende 5-(hydroxymethylen- und aminomethylen) substituierte pyrimidine
WO2008127364A3 (en) Antiviral compounds and use thereof
MY151986A (en) Adamantyl diamide derivatives and uses of same
CY1113244T1 (el) Ενωση ουρακιλης η οποια εχει ανασταλτικη δραστικοτητα σε ανθρωπινη τριφωσφαταση δεοξυουριδινης ή αλας αυτης
MX2009009952A (es) Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2, 2-difenilhexanamida.
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
AR114086A2 (es) Polvos para reconstitución
EP2183256A4 (en) THERAPEUTIC COMPOUNDS
ATE465741T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
UA45082S (uk) 1.-2. ювелірна прикраса - кольє «ile»
MXPA05009243A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados.
IN2013MU02985A (ru)
MX2012003424A (es) Tratamiento y prevencion de infeccion por el virus de inmunodeficiencia humana.
WO2008097341A3 (en) Antiviral compounds and use thereof
UA86446U (ru) Соединение 1,1'-(2"-бром-2"-хлорэтенил)-бис-(урацил) с потенциальными физиологическими свойствами
UA65915U (ru) КОГНИСИЛ - биологически активное ноотропное вещество
GB0513835D0 (en) HIV inhibitors